PROCRIT

PreclinicalSmall molecule

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

PROCRIT is one of 23 small molecule programs targeting Lymphoblastic Lymphoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lymphoblastic LymphomaActive, not recruiting

Lymphoblastic LymphomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

23 competitors in Lymphoblastic Lymphoma

#DrugCompanyPhaseTrials

Trexall

Jazz Pharmaceuticals

Approved

5 2

Cytosar

Teva

Approved

5 3

Oncovin

Eli Lilly

Approved

3 4

Dacogen

Sun Pharmaceutical Industries, Inc.

Approved

2 5

Tabloid

Akero Therapeutics

Approved

5 6

Cytoxan

BBaxter Healthcare Corporation

Approved

5 7

Purinethol

SStason

Approved

4 8

Fludara

Ninlaro

Cerubidine

HHikma Pharmaceuticals LLC

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Efficacy1 trial

Procrit Versus Placebo to Determine Efficacy in Pre-Operative Major Surgical Oncology Operations

Withdrawn·UUniversity of Louisville·Phase 2·NCT00624312

Chemotherapy1 trial

Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving Chemotherapy

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00210600·186 enrolled

Efficacy and Safety1 trial

A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients

Terminated·MM.D. Anderson Cancer Center·Phase 3·NCT00254436·50 enrolled

Lymphoblastic Lymphoma1 trial

Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy

Completed·MM.D. Anderson Cancer Center·N/A·NCT01099202·109 enrolled

Peripheral Neuropathy1 trial

A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy

Terminated· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00267007·32 enrolled

2 more indications

Randomized1 trial

A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00656448·51 enrolled

Functional Outcomes1 trial

Assess Functional Outcomes in Anemic, Critically Ill, Trauma Patients When Taking Epoetin Alfa

Terminated· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00210626·192 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for PROCRIT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PROCRIT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PROCRIT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson Pharmaceutical Research & Development, L.L.C. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

PROCRIT

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Efficacy1 trial

Chemotherapy1 trial

Efficacy and Safety1 trial

Lymphoblastic Lymphoma1 trial

Peripheral Neuropathy1 trial

Randomized1 trial

Functional Outcomes1 trial

References

Drug Info

Quick Facts

Related News